1250 GMT - Sanofi's results from a midstage study for a new asthma drug look positive, but more data will be needed to establish whether the medicine has a differentiated profile relative to a rival treatment, Citi analysts say in a research note. Results presented by the French drugmaker at a medical conference show its experimental lunsekimig asthma drug achieved a clinical benefit in a midstage study, but a late-stage trial will be needed to determine whether it beats AstraZeneca's Tezspire, the analysts say. Citi estimates lunsekimig could reach annual sales of 1.8 billion euros at its peak across asthma and chronic obstructive pulmonary disease. Sanofi shares fall 1.1%.